Changes coming in 2010 for first-line treatment of multiple myeloma
According to a study published by Majestic Research's Market Research Group, data presented at the 2009 American Society of Hematology (ASH) 2009 Annual Meeting in December has had a profound effect on the way many hematologists and oncologists intend to treat multiple myeloma, a cancer of the plasma cells.
Specifically, almost half of those specialists polled say they expect to start using the thalidomide analog Revlimid (lenalidomide), the antineoplastic agent Velcade (bortezomib), or both in combination.
In this context, the most recalled study from ASH was MM-015, a Phase III study that looked at the continuous use of Revlimid with Melphalan and Prednisone. Research shows that many experts believed that the results of MM-015 were significant enough to encourage using Revlimid in treating multiple myeloma.
In short, this year we should expect a substantial change to the first-line treatment of this difficult-to-treat cancer.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
